Head-To-Head Survey: Atossa Genetics (NASDAQ:ATOS) and STERIS (NYSE:STE)

STERIS (NYSE:STE) and Atossa Genetics (NASDAQ:ATOS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares STERIS and Atossa Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
STERIS	12.15%	14.34%	9.58%
Atossa Genetics	N/A	-65.56%	-57.74%

Valuation and Earnings

This table compares STERIS and Atossa Genetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.46 billion	3.92	$614.64 million	$7.17	30.46
Atossa Genetics	N/A	N/A	-$34.77 million	($3.60)	-1.49

STERIS has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

STERIS has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Atossa Genetics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for STERIS and Atossa Genetics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0	2	6	0	2.75
Atossa Genetics	2	0	2	1	2.40

STERIS presently has a consensus price target of $275.20, suggesting a potential upside of 26.00%. Atossa Genetics has a consensus price target of $68.33, suggesting a potential upside of 1,174.88%. Given Atossa Genetics’ higher probable upside, analysts plainly believe Atossa Genetics is more favorable than STERIS.

Institutional & Insider Ownership

94.7% of STERIS shares are held by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are held by institutional investors. 1.1% of STERIS shares are held by insiders. Comparatively, 9.5% of Atossa Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

STERIS beats Atossa Genetics on 10 of the 14 factors compared between the two stocks.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier, sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and electric-powered dental instruments, infection control products, conscious sedation, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

About Atossa Genetics

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.